Washington University: Alzheimer's Peripheral Immune Cells Drive Brain Damage

• Researchers at Washington University found that brain damage in Alzheimer's-like conditions in mice may stem from immune cells activated outside the brain.
• Eliminating classical dendritic cells (cDC1s) in genetically prone mice reduced brain T cells and protected against neurodegeneration, even with continued tau buildup.
• The study suggests that tau accumulation and the immune response causing brain damage are separate processes, with T cells potentially activated in peripheral lymph nodes.
• This research opens new therapeutic avenues by targeting the peripheral immune system, potentially bypassing the challenge of the blood-brain barrier.
• While promising, the findings in mice do not yet confirm the same mechanism in human Alzheimer's patients.

The findings suggest that tau accumulation and the immune response causing subsequent brain damage may be separate processes.

Researchers at Washington University School of Medicine in St. Louis have unveiled new insights into the progression of Alzheimer's disease and related neurological conditions, suggesting that brain damage may originate from immune responses outside the central nervous system. Their study, published in Nature Neuroscience, utilized mouse models to investigate the role of T cells in the destruction of brain cells associated with neurodegeneration.

The team observed mice exhibiting Alzheimer's-like neurodegeneration and found that by inhibiting specific immune responses, they could significantly reduce brain damage. A key discovery involved the elimination of classical dendritic cells, known as cDC1s, in mice genetically predisposed to tau-related disease. This intervention led to a sharp decrease in T cells within the brain and provided protection against neurodegeneration. Remarkably, these mice still developed tau tangles, a hallmark of Alzheimer's, but experienced less brain damage and maintained their cognitive abilities.

These findings challenge conventional understanding by proposing that the accumulation of tau protein and the subsequent immune response leading to brain damage might be distinct processes. Dr. David Holtzman, a professor of neurology at Washington University and the study's senior author, highlighted this separation. His laboratory had previously demonstrated that removing T cells from mice could prevent much of the brain damage linked to tau buildup, prompting the current investigation into the activation site of these T cells.

The research posits a novel mechanism for how immune cells contribute to brain damage in Alzheimer's. While T cells are known to accumulate in the brain alongside tau buildup, the study suggests these cells may be activated in other parts of the body before migrating to the brain. The researchers initially found very few cDC1 cells within the brains of mice with tau pathology, directing their attention to peripheral tissues.

When cDC1 cells were removed from lymph nodes and other peripheral tissues, the mice exhibited a substantial reduction in T cells within their brains, particularly CD8 T cells, which are capable of destroying targeted cells. This reduction in T cells correlated directly with decreased neurodegeneration, despite the continued presence of tau buildup. The scientists hypothesize that damage caused by tau in the brain might lead brain cells to release material that drains into lymph nodes located in the neck. Within these lymph nodes, dendritic cells could then activate T cells, which subsequently travel to the brain and contribute to further damage.

This proposed pathway offers a compelling explanation for how peripheral immune activity could drive central nervous system pathology, fundamentally altering the perspective on where the disease process might be most effectively intercepted.

The implications of these findings for future therapeutic strategies are significant. Dr. Holtzman emphasized a major challenge in developing treatments for neurological diseases: the necessity of engineering drugs to penetrate the blood-brain barrier to reach the central nervous system. However, the new research suggests that it might not be necessary to deliver drugs directly into the central nervous system to mitigate neurodegeneration.

By targeting the peripheral immune system, researchers could potentially bypass the complex hurdle of the blood-brain barrier. The study points to the possibility that existing treatments designed to manipulate T cells could be repurposed or adapted to target the peripheral immune system as a viable strategy for future research into Alzheimer's and related conditions. It is crucial to note, however, that while these mouse model findings are promising, the study does not yet establish that the same process occurs in human patients with Alzheimer's disease. Further research will be needed to translate these discoveries into human therapies.

Source: Original reporting via Courthouse News Service